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Abstract 
Background: Human DNA polymerase β (polβ) is a small monomeric protein that is essential for short-patch base 
excision repair. It plays an important role in regulating the sensitivity of tumor cells to chemotherapy.
Methods: We evaluated the mutation of polβ in a larger cohort of esophageal cancer (EC) patients by RT-
PCR and sequencing analysis. The function of the mutation was evaluated by CCK-8, in vivo tumor growth, and 
flow cytometry assays.
Results: There are 229 patients with the polβ mutation, 18 patients with A613T mutation, 12 patients with 
G462T mutation among 538 ECs. Analysis results of survival time showed that EC patients with A613T, G462T 
mutation had a shorter survival than the others (P < 0.05). CCK-8 and flow cytometry assays results showed the 
A613T, G462T EC9706 cells were less sensitive than WT cells to 5-FU and cisplatin (P < 0.05). Experiments results in 
vivo showed that the tumor sizes of A613T and G462T group were larger than WT and polβ−/− groups (P < 0.05).
Conclusions: In this study, we discovered A to T point mutation at nucleotide 613 (A613T) and G to T point mutation 
at nucleotide 462 (G462T) in the polβ gene through 538 EC patients cohort study. A613T and G462T variant of DNA 
polymerase β weaken chemotherapy sensitivity of esophageal cancer.
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Background
DNA polymerase β (polβ) is a protein which exists in mam-
malian cells [1]. Polβ belongs to the DNA polymerase fam-
ily, and it is closely related to base excision repair (BER) 
[2–5]. BER is one of the most important DNA repair meth-
ods [6]. Through nonhomologous end joining, polβ partici-
pates in the repair of DNA double-strand break [7, 8].
Tumorigenes is involves a series of processes includ-
ing genetic and epigenetic changes [9]. 30% of the tumors 
were reported to have a polβ mutation [10]. Abnormal 
expression of polβ leads to a highly mutagenic toler-
ance phenotype [11, 12]. Mutations polβ gene had been 
reported in a variety of cancers [13–17].
Esophageal cancer (EC) is one of the high incidence 
of malignant tumors in the world. Some research results 
showed that polβ gene mutation is exited in EC tissues 
[18, 19]. After lots of previous work, we discovered A to 
T point mutation at nucleotide 613 (A613T) and G to T 
point mutation at nucleotide 462 (A462T) in the polβ 
gene through 538 EC patients cohort study, and these 
two mutations are related to patients chemotherapy sen-
sitivity. In this study, we analyze the relationship between 
polβ mutation and chemotherapy in ECs.
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Methods
Patients and tissue specimens
From 2000 to 2015, we collect a total of 538 tissues sam-
ple of EC patients in the First Affiliated Hospital of Zheng-
zhou University and Oncology Hospital of Linzhou City. 
The clinicopathologic characteristics of the 538 EC cases 
included in this study are presented in Table 1. Diagnosis by 
pathology experts, the tissues were stored in liquid nitrogen 
immediately. All patients were informed in advance and 
signed explicit informed consent. This study was approved 
by the ethics committee of Zhengzhou University.
Cell and lentivirus infection of cells
EC cell line EC9706 and polβ null (polβ−/−) EC9706 
cells [20] were established in our laboratory before. Full-
length wild-type, A613T and G462T mutation polβ were 
amplified by PCR. These fragments were cloned into 
the lentiviral vector (LV5) to expression LV5-WT, LV5-
A613T and LV5-G462T. Co-transfected 4.5  μg of that 
three LV5, 3.5 μg PG-P2-REV, 1.5 μg PG-P1-VSVG plas-
mids and 0.5 μg Lipofectamine2000 into 293T cells. Then 
we performed the lentiviral infection polβ−/− EC9706 
cells. When polβ−/− EC9706 cells at a confluence of 60%, 
removed cell culture media. Culture cells with the virus-
containing medium and polybrene. The MOI of lentivi-
ral is 10. Stable cell lines were generated by puromycin 
selection. The cells were divided into four groups: wild-
type EC9706 cells (WT), G462T mutation EC9706 cells 
(G462T), A613T mutation EC9706 cells (A613T) and 
polβ null EC9706 cells (polβ−/−).
RNA isolation and RT‑PCR
Using the Total RNA Kit I (R6834-01; Omega, USA) 
extracted RNA according to the manufacturer’s instruc-
tions. Then RNA was reversely transcribed to cDNA by 
reverse transcription Kit (Thermo, USA). The cDNA 
was performed PCR amplification. The fragments were 
extracted for agarose gel electrophoresis after PCR.
DNA sequencing analysis
PCR amplification products were cloned into pGEM-T 
vectors, then transformed into DH5α Escherichia coli. 
Bacteria were amplified in liquid LB medium. The bacte-
rial suspension was sent to sequencing analysis by San-
gon Biotech (Shanghai).
qRT‑PCR assay
With the extracted RNA, the first strand cDNA Synthesis 
Kit was used to synthesize cDNA with an oligo dT primer 
kit. TaqMan assays were used to detect the expression 
of polβ mRNA. Primers were designed by Primer Pre-
mier 5.0 software. PCR conditions were as follows: 50 °C 
2  min; 95  °C 2  min; 95  °C 15  s, 55  °C 30  s, 72  °C 30  s, 
for 45 cycles. The 2−ΔCt method was used to evaluate the 
relative expression of the target gene in the three groups. 
Primers sequences are as follows:
Forward  5′ ACATGCTCACAGAACTCGCAAA 3′.
Reverse  5′ TCCAGGCAATTTCTTAGCTTC 3′.
Probe  5′ AAGAACGTGAGCCAAGCTATCCAC 3′.
We used β-actin as an endogenous control for normali-
zation. Primers sequences are as follows:
Forward  5′ AACCGCGAGAAGATGACCCA 3′.
Reverse  5′ CACCGGAGTCCATCACGAT 3′.
Probe  5′ CTGTGCTATCCCTGTACGCCTCT 3′.
Western blotting
The total protein content of cultured cells was extracted 
using RIPA buffer containing phenylmethanesulfonyl-
fluoride (PMSF). A BCA protein assay kit (Beyotime, 
Haimen, China) was used to determine the protein con-
centration. Proteins were subjected to sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
and transferred onto PVDF membranes. After block-
ing, the membranes were incubated overnight at 4  °C 
with diluted (1:300) primary antibodies (polyclonal rab-
bit anti-polβ; Proteintech). Following extensive wash-
ing, membranes were incubated with diluted (1:3000) 
horseradish peroxidase-conjugated goat anti-rabbit IgG 
(Santa Cruz). Signals were determined with a chemilu-
minescence detection kit (Amersham Pharmacia Biotech, 
Piscataway, NJ). An antibody against β-actin (Santa Cruz 
Biotechnology) served as an endogenous reference.
CCK‑8 assay
To confirm the effect of A613T and G462T muta-
tion on chemotherapy, CCK-8 assay was performed in 
Table 1 Clinicopathological characteristics of EC patients
Variables Gender Age Tumor location Lymph node metas‑
tasis
Differentiation TNM stage
Male Female ≥60 <60 Middle Lower Negative Positive Well Moderate Poor I II III
n 365 173 337 201 421 117 323 215 151 269 118 154 263 121
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the four groups of EC9706 cells (WT, A613T, G462T, 
and polβ−/−). The drug concentration of 5-fluorouracil 
(5-FU) is 0–50 μg/mL, cisplatin is 0–8 μg/mL. The cells 
were seeded into a 96-well plate at a density of 3 × 104/
well. 24 h later removed the medium, washed by PBS for 
twice, and replaced with fresh medium drugs. After 48 h 
of drugs exposure, used Cell Counting Kit-8 (Dojindo, 
Kumamoto, Japan) to detect absorbance at 450  nm by 
Microplate Reader (Bio-Rad, Hercules, CA, USA). The 
experiment was repeated three times.
Apoptosis assay
The four groups of EC9706 cells (WT, A613T, G462T and 
polβ−/−) were incubated overnight in complete medium. 
The attached cells were washed once with PBS, and then 
replaced with fresh medium containing 40  μg/mL 5-FU 
or 4 μg/mL cisplatin. Cells were harvested at 48 h post-
transfection by trypsinization. Cells were resuspended at 
106 cells/mL in 1× binding buffer. After double staining 
with FITC-Annexin V and propidium iodide (PI) using 
the FITC Annexin V Apoptosis Detection Kit I (BestBio, 
Shanghai, China), cells were analyzed using an FACScan 
flow cytometer (BD Biosciences, USA) equipped with 
Cell Quest software (BD Biosciences).
In vivo tumor growth assay
Transfected with lentivirus of four groups cells (WT, 
A613T, G462T, and polβ−/−) (1 × 107) were subcutane-
ously inoculated into 6-week-old female BALB/c nude 
mice at the dorsal flank. The mice were randomly divided 
into two groups: cisplatin group and 5-FU group. Each 
group had 5 mice. Cisplatin group was given to the mice 
in a dosage of 3  mg/kg, once weekly for 4  weeks. 5-FU 
was given to the mice in a dosage of 10 mg/kg, 2 days a 
time, and last 2 weeks. Then execute the mice to take out 
the tumor to survey tumor volume. All the operation of 
the mice is in line with the specification of National Insti-
tutes of Health.
Statistical analysis
The software for statistical analysis is SPSS 21.0 (Chicago, 
IL, USA). Use t test and one-way analysis of variance to 
test difference among groups. Use the Kaplan–Meier and 
log-rank test to test the survival time. The difference was 
statistically significant when P < 0.05.
Results
A613T and G462Tmutations in esophageal cancer
In order to study polβ mutation in EC, we build a cohort 
of 538 EC patients. The mutations of polβ were detected 
by PCR and DNA sequencing. There are 229 (42.57%) 
patients with the polβ mutation (Table  2), 18 (3.35%) 
patients with A613T mutation, 12 (2.23%) patients with 
G462T mutation among 538 ECs (Fig. 1). A613T muta-
tion takes in 7.86% of 229 polβ mutations, and G462T 
takes in 5.24% of 229 polβ mutations. The correspond-
ing changes in amino acids of A613T and G462T muta-
tions and their location in polβ protein are presented in 
Table 2.
A613T and G462T mutations are related to the response 
to postoperative chemotherapy and shorten survival of EC 
patients
We analyzed the different survival time among patients 
with A613T, G462T mutation and others by Kaplan–
Meier method. We used the Kaplan–Meier to analyze 
the difference in survival time between the patients with 
A613T mutation and wild type, the patients with A613T 
mutation and others (all patients except A613T muta-
tion), the patients with A613T mutation and patients 
with other mutations (all patients with mutations 
except A613T mutation), based on follow-up visits of 
EC patients. The average survival time of patients with 
A613T mutation (18 cases) is 6.39 months, patients with 
wild-type (309 cases) is 38.35 months, and patients with 
other mutations (520 cases) is 30.89 months. Also, ana-
lyze the difference of G462T in the same way. The average 
survival time of patients with G462T mutation (12 cases) 
is 7.17  months, and patients with other mutations (526 
cases) are 30.89  months. Analysis results show that EC 
patients with A613T or G462T mutation had a shorter 
survival than the others (P < 0.05, Fig. 2).
Polβ mRNA and protein expression levels in EC patients 
and cell lines
The expression levels of polβ mRNA and protein of 
patients samples and four groups cells (polβ−/−, WT, 
A613Tand G462T) were detected by qRT-PCR and west-
ern blot assays. Compared to adjacent non-tumor tissues, 
polβ mRNA expression in tumor tissue was found sig-
nificantly higher (P < 0.05; Fig. 3a). All the EC patients’ 
samples were subjected to Western blot analysis, and the 
results were represented as polβ/β-actin. We randomly 
choose some samples as a representative. The polβ pro-
tein expression levels of adjacent non-tumor tissues of 
A613T mutation patients (A1–A3), G462T mutation 
patients (A4–A5), tumor tissues of A613T mutation 
patients (T1–T3, match to A1–A3) and polβ−/−, WT, 
A613T cell lines are presented in Fig.  3b. The standard 
error bars of patient samples are obtained from ran-
domly selected patient samples, and the standard devia-
tion bars of cell lines are obtained from three replications. 
The polβ protein expression levels of tumor tissues of 
G462T mutation patients (T4–T6, match to A4–A5) and 
G462T cell line are presented in Fig.  3c. We could find 
that the polβ protein expression levels of tumor tissues 
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of these two mutation patients were significantly higher 
than that of adjacent non-tumor tissues (P < 0.05). There 
was almost no expression of polβ in the polβ−/− cell line. 
polβ protein expression levels of WT, A613T, and G462T 
cell lines were significantly higher than that of adjacent 
non-tumor tissues (P < 0.05), and had no significant dif-
ference with tumor tissues.
A613T and G462T mutations weaken the proliferation 
inhibition effect of chemotherapeutics in EC9706 cells
In order to further study the relationship between polβ 
mutation and resistance to chemotherapy in ECs, we 
performed CCK-8 assay on four group cells for prolifera-
tion inhibition effect of 5-FU and cisplatin. The A613T, 
G462T cells were less sensitive than WT cells to 5-FU 
and cisplatin (P < 0.05; Fig. 4). The results were in agree-
ment with the clinical observation, that A613T and 
G462T mutations patients have less chemotherapy sen-
sitivity and short survival time, indicated that A613T, 
G462T mutation are associated with poor response to 
chemotherapy of ECs.
A613T and G462T mutations weaken the apoptosis effect 
of chemotherapeutics in EC9706 cells
Our flow cytometry results indicated that the apop-
tosis levels of the A613T and G462T groups with 5-FU 
and cisplatin were weaken compared to the polβ−/− and 
WT groups with5-FU and cisplatin (P < 0.05; Fig. 5). We 
Table 2 Mutations in 538 EC patients
GenBank Acc# M13140.1
Gene variation n Proportion % Amino acid variation Domain
375 nt: A → G 21 3.90 88 aa: I → V 8kD domain
454 nt: T → C 19 3.53 114 aa: F → S Thumb domain
462 nt: G → T 12 2.23 117 aa: E → termination mutation Thumb domain
466 nt: G → A 32 5.95 118 aa: G → E Thumb domain
613 nt: A → T 18 3.35 167 aa: K → I Palm domain
648 nt: G → C 20 3.72 179 aa: G → R Palm domain
660 nt: A → G 27 5.02 183 aa: R → G Palm domain
665 nt: T → C 8 1.49 184 aa: G → G Palm domain
676 nt: G → A 15 2.79 188 aa: S → N Palm domain
737 nt: A → T 6 1.12 208 aa: P → P Palm domain
740 nt: A → G 9 1.67 209 aa: K → K Palm domain
832 nt: A → G 11 2.04 240 aa: Q → R Palm domain
853 nt: A → G 7 1.30 247 aa: E → G Palm domain
854nt: A → C, and 855nt: A → C 12 2.23 247 aa: E → D, and 248 aa: K → Q Palm domain
177–234 nt: deletion 12 2.23 22 aa: frameshift mutation;
26 aa: termination mutation
8kD domain
Total 229 42.57 – –
Fig. 1 DNA sequence analysis of ECs. Identification of the A613T and G462T mutations in ECs with DNA sequencing
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Fig. 2 Survival curves of ECs. a–c Patients with A613T mutation survival and the patients with wild-type polβ survival, others survival and other 
polβ mutation survival enrolled. d–f Patients with G462T mutation survival and the patients with wild-type polβ survival, others survival and other 
polβ mutation survival enrolled
Fig. 3 Expression levels of polβ mRNA and protein of patients samples and four groups cells (polβ−/−, WT, A613T, and G462T). a Expression levels 
of polβ mRNA of patients samples. Compared to adjacent non-tumor tissues, polβ mRNA expression in tumor tissue was found significantly higher. 
b The polβ protein expression levels of adjacent non-tumor tissues of A613T mutation patients (A1–A3), G462T mutation patients (A4–A5), tumor 
tissues of A613T mutation patients (T1–T3) and polβ−/−, WT, A613T cell lines. c The polβ protein expression levels of tumor tissues of G462T muta-
tion patients (T4–T6) and G462T cell line (*P < 0.05)
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conclude that A613T and G462T mutations weaken the 
apoptosis effect of chemotherapeutics in EC9706 cells.
A613T and G462T mutations weaken the proliferation 
inhibition effect of chemotherapeutics in vivo
Experiments in  vivo further confirmed the relationship 
between A613T, G462T mutation and poor response 
to chemotherapeutics. The tumor sizes of A613T and 
G462T group were larger than WT and polβ−/− groups 
(P  <  0.05; Fig.  6). These results indicated that A613T, 
G462T mutation weaken the inhibition proliferation of 
chemotherapeutics in vivo.
Discussion
Esophageal carcinoma is one of the most common malig-
nant tumors in the world. About 200,000 people die 
from esophageal cancer each year. There is great pro-
gress in the diagnosis and treatment of ECs, however, 
patients still have the problem of rapid progression and 
poor prognosis [21]. Surgery also has its disadvantages 
for patients and surgeons. The majority of EC patients 
with advanced choice of conservative treatment, such as 
chemotherapy. Chemotherapy is one of the main con-
servative treatments for EC. So far, the therapeutic effi-
ciency of chemotherapeutics for EC has not been very 
well. The 5-year survival rate of EC wandered 10–30% 
and the probability of recurrence of the tumor is reached 
to 60–80% [22, 23]. Therefore, study of the factors that 
affect the sensitivity of chemotherapy is the focus of our 
research. In recent years, some genes have been reported 
that affect the sensitivity of chemotherapy, such as DNA 
damage repair proteins, apoptosis genes and cycle regu-
lation genes [24–26].
Polymerase β closely related to BER for its polymerase 
and deoxyribose phosphate lyase activities. It also can 
maintain the integrity and stability of genomic [27]. polβ 
exists in a single nucleotide gap and leads to removal of 
the dRP group [28–30]. 30% of the tumors were reported 
to have a polβ mutation [10]. Many of these results are 
from a single amino acid substitution.
Fig. 4 Sensitivity of cell lines to cisplatin and 5-FU. a A613T and G462T mutations weaken the proliferation inhibition effect of 5-FU. Concentration 
of 5-FU was 0 to 50 μg/mL. b A613T and G462T mutations weaken the proliferation inhibition effect of cisplatin. Concentration of cisplatin was 0 
to 8 μg/mL. WT: wild-type EC9706 cells; A613T: A613T mutation EC9706 cells; G462T: G462T mutation EC9706 cells; polβ−/−: polβ null EC9706 cells 
(*P < 0.05)
Fig. 5 A613T and G462T mutations weaken the apoptosis effect of chemotherapeutics in EC9706 cells. The apoptosis levels of the A613T and 
G462T groups with 5-FU and cisplatin were weaken compared to the polβ−/− and WT groups with 5-FU and cisplatin (*P < 0.05)
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The present study presents the A613T, G462T mutation 
of polβ gene in EC patients. The A613T, G462T muta-
tions were associated with chemotherapy for EC. Some 
studies have shown that polβ exhibits opposite functions: 
an oncogene or as a tumor suppressor gene [31–33]. To 
detect the incidence of A613T, G462T mutation in EC, 
we established a cohort of 538 EC patients. The polβ 
mutation was detected in 229 (42.57%) of them. Among 
229 polβ mutation cases, A613T point mutation was 
detected in 18 patients (7.86%) and G462T point muta-
tion was detected in 12 patients (5.24%). The patients 
with A613T, G462T mutation had shorter survival time 
than the others. The results of CCK-8, flow cytometry 
and in  vivo tumor growth assays indicated that polβ−/− 
group cells are more sensitive than wild-type to 5-FU and 
cisplatin, and A613T, G462T mutation weaken the sen-
sitivity of cells to 5-FU and cisplatin. The reason may be 
that polβ belongs to the DNA polymerase family, and it 
is closely related to BER, which is one of the most impor-
tant DNA repair methods. That means polβ participates 
in the repair of DNA double-strand break. The A613T 
and G462T mutation may change some functions of polβ. 
Our clinical and experimental data indicate that A613T, 
G462T mutation has a tumor-promoting property, and 
in comparison to the wild-type polβ gene in EC, it may 
shorten survival of EC patients.
This study confirms that the A613T, G462T mutation of 
polβ desensitize EC patients to chemotherapy. Thus, the 
A613T, G462T mutation polβ gene may be clinically useful 
for EC patients to predicting the responsiveness to chemo-
therapy. It may serve as prognostic biomarkers for EC.
Conclusions
In this study, we discovered A to T point mutation at 
nucleotide 613 (A613T) and G to T point mutation at 
nucleotide 462 (G462T) in the polβ gene through 538 EC 
patients cohort study. A613T and G462T variant of DNA 
polymerase β weaken chemotherapy sensitivity of esoph-
ageal cancer.
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